

## For Health Professionals Who Care For Cancer Patients

### Inside This Issue:

- **Editor’s Choice – New Programs:** Daratumumab in Combination with Bortezomib (UMYDARBD) or Lenalidomide (UMYDARLD) for Multiple Myeloma, Oxaliplatin to Replace Cisplatin-Based Therapies (GIGAVCOXT, GIGAVFFOXT) for HER2-Positive Advanced Gastric and Related Adenocarcinomas
- **Provincial Systemic Therapy Program Policies –** Daratumumab Added to PSTP Policy III-60
- **Drug Update –** Oral Etoposide Capsules Available, Medical Patient Assistance Programs
- **Benefit Drug List – New:** GIGAVCOXT, GIGAVFFOXT, UMYDARBD, UMYDARLD; **Revised:** GUTEM, LUAVCRIZ, LUAVCRIZF
- **Cancer Drug Manual – New:** Inotuzumab ozogamicin; **Revised:** Carfilzomib, Clodronate, Daratumumab, Pamidronate, Pembrolizumab, Zoledronic Acid
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts – New:** GIGAVCOXT, GIGAVFFOXT, UMYDARBD, UMYDARLD; **Revised:** CNCCNU, CNETO, CNPROC, CNTEM60, CNTEMOZ, CNTEMOZMD, CNTMZETO, GIGAVTR, UGILAN, UGIOCTLAR, GUTEM, ULKMFURUX, ULKPCVRUX, LUAVCRIZ, ULUAVPMTN, SAVDC; **Reformatted PPPOs:** BRAJANAS, BRAJEXE, BRAJLET, BRAJLHRHT, BRAJTAM, BRAVANAS, BRAVCLOD, BRAVEXE, BRAVLET, BRAVMEG, BRAVTAM, CNAJ12TZRT, CNAJTZRT, CNB, CNCAB, CNELTZRT, CNQUIN, GIAJCAP, GIAVCAP, GIPAVCAP, GUPNSAA, HNNAVCAP, HNSAVTAM, LUAVAFAT, ULUAVCER, LUAVCRIZ, LUAVCRIZF, LUAVERL, LUAVGEFF, LUAVMTNE, LUSCPOE, LYCHLOR, LYCSA, ULYMFBEX, MYMP
- **Website Resources and Contact Information**

## EDITOR’S CHOICE

### NEW PROGRAMS

Effective 01 February 2019, the BC Cancer Provincial Systemic Therapy Program has approved the following treatment programs:

#### Multiple Myeloma:

**Daratumumab in Combination with Bortezomib/Dexamethasone (UMYDARBD) or Lenalidomide/Dexamethasone (UMYDARLD) for Multiple Myeloma** – The Provincial Systemic Therapy Program has approved daratumumab in combination with either bortezomib/dexamethasone (Bor-dex) or lenalidomide/dexamethasone (Len-dex) for multiple myeloma after failure of at least 1 line of prior therapy. Patients must be sensitive to bortezomib to be eligible for UMYDARBD and sensitive to lenalidomide to be eligible for UMYDARLD. Full details for eligibility are outlined in the protocols.

Daratumumab is a human IgGκ monoclonal antibody that targets CD38 which is highly expressed on myeloma cells. In a Phase III randomized controlled trial (CASTOR), the addition of daratumumab to Bor-dex improved progression free survival (mPFS not yet reached vs. 7.2 mo, HR 0.39 [95% CI 0.28 to 0.53]) and complete response rates (19.2% vs. 9.0%, p=0.001).<sup>1</sup> Final survival analysis is pending. The addition of oral cyclophosphamide will be permitted based on evidence presented in a single-arm Phase II trial (LYRA).<sup>2</sup>

These results were similarly shown in a separate Phase III randomized controlled trial (POLLUX), where the addition of daratumumab to Len-dex showed a reduction in the risk of disease progression or death (18.5% vs. 41%, HR 0.37 [95% CI 0.27 to 0.52]) and an improved complete response rate (43.1% vs. 19.2%,  $p < 0.001$ ).<sup>3</sup>

Daratumumab is associated with tolerable, but not insignificant, adverse effects. In particular, about 50% of patients treated with daratumumab experienced infusion-related reactions.<sup>1</sup> A majority (98%) of these reactions occurred with the first infusion, and primarily during or within the first 4 hours of infusion. As such, strict guidelines for premedication (with dexamethasone, acetaminophen, diphenhydramine and montelukast), daratumumab administration rate, and patient observation (during and after infusion) are clearly outlined in the chemotherapy protocols.

Daratumumab also follows a complicated dosing regimen that differs from cycle to cycle; dosing instructions on the chemotherapy protocols should be carefully observed. Of note, there are two administration options for the first daratumumab dose in cycle 1 (i.e. cycle 1 day 1):

- Standard regimen – give daratumumab over 1 day
- Alternative regimen – give daratumumab over 2 days (to accommodate the shorter operational hours of most ambulatory cancer clinics)

### **Gastrointestinal:**

**Oxaliplatin in Combination with Trastuzumab and 5-Fluorouracil (GIGAVFFOXT) or Capecitabine (GIGAVCOXT) for HER2-Positive Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma** – The 2010 landmark ToGA trial established cisplatin, 5-fluorouracil/capecitabine and trastuzumab (GIGAVCCT, GIGAVCFT) as the standard of care for these GI malignancies.<sup>4</sup> Since then, cisplatin has been largely replaced by oxaliplatin due to improved tolerability. In a retrospective study, trastuzumab with FOLFOX resulted in a median overall survival of 17 months and a median progression free survival of 9 months. These results did not appear to be numerically inferior to the clinical benefit seen in the ToGA trial.<sup>5</sup> Trastuzumab with FOLFOX was also more convenient to administer and had acceptable tolerability.

The BC Cancer Gastrointestinal Tumour Group has now formalized the oxaliplatin-based regimens as the preferred standard of care in this patient population. Patients currently on the cisplatin-based regimens may remain on these regimens or switch to the oxaliplatin-based regimens without the need to apply for BC Cancer Compassionate Access Program (CAP) approval.

### **References:**

1. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. *N Engl J Med* 2016; 375:754-766.
2. Yimer HA, Melear J, Faber E, et al. Lyra: A Phase 2 Study of daratumumab (dara), plus cyclophosphamide, bortezomib and dexamethasone in newly diagnosed and relapsed patients (Pts) with Multiple Myeloma (MM). Oral and poster abstract presented at: 60<sup>th</sup> ASH Annual Meeting; 2018 Dec 1; San Diego, CA.
3. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med* 2016; 375:1319-1331.
4. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:9742:687-697.
5. Soularue É, Cohen R, Tournigand C, et al. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. *Bull Cancer* 2015;102:324-331.

## PROVINCIAL SYSTEMIC THERAPY PROGRAM POLICIES

### DARATUMUMAB ADDED TO PSTP POLICY III-60

Daratumumab has been added to the Provincial Systemic Therapy [Policy III-60](#) – Drug Reaction Management – Physician Coverage During Delivery of Selected Systemic Therapy Drugs.

## DRUG UPDATE

### ORAL ETOPOSIDE CAPSULES AVAILABLE

Etoposide *oral capsules* are once again available in Canada. Stock is now available in BC, but supplies will be on allocation by the manufacturer, Bristol Myers-Squibb, to ensure they continue to be available across Canada.

### MEDICAL PATIENT ASSISTANCE PROGRAMS

The BC Cancer Medical Staff Engagement Society (MSES) generously provided financial support to organize a comprehensive, up-to-date listing of oncology medical patient assistance programs offered by pharmaceutical companies. The listing can be found at: [www.bccancer.bc.ca/mpap](http://www.bccancer.bc.ca/mpap). \* Future updates to such provisional bridging programs will be announced periodically in the Systemic Therapy Update.

\*Located on the BC Cancer Systemic Therapy website under Health Professionals > Systemic Therapy > Reimbursement & Forms

## BENEFIT DRUG LIST

### NEW PROGRAMS

Effective 01 February 2019, the following treatment programs have been added to the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Capecitabine, Oxaliplatin and Trastuzumab (HERCEPTIN)	GIGAVCOXT	Class I
Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Using Oxaliplatin, Fluorouracil, Leucovorin, and Trastuzumab (HERCEPTIN)	GIGAVFFOXT	Class I
Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone with or without Cyclophosphamide	UMYDARBD	Restricted
Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone	UMYDARLD	Restricted

## BENEFIT DRUG LIST

### REVISED PROGRAMS

Effective 01 February 2019, the following treatment programs have been revised on the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Therapy for Advanced Renal Cancer using Temsirolimus	GUTEM	Class I
Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib	LUAVCRIZ	Class I
First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib	LUAVCRIZF	Class I

## CANCER DRUG MANUAL

### NEW MONOGRAPHS AND PATIENT HANDOUTS

The following drug is NOT a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). Its corresponding Interim Monograph and Patient Handout are made available for reference only. All BC Cancer drug monographs and patient handouts can be accessed on the BC Cancer [Drug Index](#).

The **Inotuzumab ozogamicin Interim Monograph and Patient Handout** have been developed with expert review provided by Dr. David Sanford (hematologist) of the BC Cancer Leukemia and Bone Marrow Transplant Tumour Group. Inotuzumab ozogamicin is an antibody-drug conjugate composed of a humanized monoclonal antibody (inotuzumab) linked to a small molecule cytotoxic agent (N-acetyl-gamma-calicheamicin). Inotuzumab ozogamicin is used as monotherapy in adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. The usual dose for cycle 1 is 0.8 mg/m<sup>2</sup> on day 1 and 0.5 mg/m<sup>2</sup> on days 8 and 15, given intravenously. Cycle 2 and optional additional cycles are dosed based on whether a complete response was achieved in cycle 1, and are given every 3 to 4 weeks.

Highlights of these documents:

- Premedication with a corticosteroid, antihistamine, and antipyretic is recommended for all patients prior to each dose to prevent infusion-related reactions
- Myelosuppression and infections are commonly reported
- Severe, and sometimes, fatal veno-occlusive disease/sinusoidal obstruction syndrome has been reported; monitor for elevated bilirubin, hepatomegaly, rapid weight gain and ascites
- Other rare, but serious, side effects include tumour lysis syndrome and QT-prolongation

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs, Patient Handouts and Chemotherapy Preparation and Stability Chart (CPSC) are listed below:

**Carfilzomib Monograph**

- *Cautions, Special Populations, and Side Effects:* updated incidence and risk factors for cardiac failure

**Clodronate Patient Handout**

- Revised statements on indications and drug interactions

**Daratumumab Monograph, Patient Handout and CPSC**

- *Dosing:* added BC Cancer protocol and standard dosing

**Pamidronate Patient Handout and CPSC**

- Added adjuvant indications and expanded on drug interactions
- *CPSC:* added Pfizer as new brand

**Pembrolizumab Monograph**

- *Uses:* updated Health Canada approved indications
- *Dosing:* added fixed-dose regimens and updated pediatric dosing

**Zoledronic Acid Patient Handout**

- Added adjuvant indications and expanded on drug interactions

LIST OF REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Protocol Title
GIGAVCOXT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Capecitabine, Oxaliplatin and Trastuzumab (HERCEPTIN)
GIGAVFFOXT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin, and Trastuzumab (HERCEPTIN)
UMYDARBD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone with or without Cyclophosphamide

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)				
CODE	Protocol	PPPO	Patient Handout	Protocol Title
UMYDARLD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
CNCCNU	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Reformatted, test updated</i>	Lomustine (CCNU) for Treatment of Recurrent Malignant Brain Tumours
CNETO	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Reformatted, test updated</i>	Palliative Treatment of Patients with Recurrent Malignant Gliomas and Ependymoma using Low-Dose Etoposide
CNPROC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Reformatted, test updated</i>	Standard Procarbazine for Second-Line Treatment of Recurrent Brain Tumour
CNTEM60	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Reformatted, test updated</i>	Therapy for Newly Diagnosed Malignant Brain Tumours with MGMT Methylation in Elderly Patients using Temozolomide
CNTEMOZ	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Reformatted, test updated</i>	Therapy for Malignant Brain Tumours using Temozolomide
CNTEMOZMD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Reformatted, test updated</i>	Therapy for Malignant Brain Tumours using Metronomic Dosing of Temozolomide
CNTMZETO	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Reformatted, test updated</i>	Therapy for Recurrent Malignant Brain Tumours using Temozolomide and Etoposide
GIGAVTR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility updated</i>	Continuation of Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using Trastuzumab
UGILAN	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Duration of approved treatment updated</i>	Symptomatic Management of Functional Carcinoid and Neuroendocrine Tumours of the GI Tract using Lanreotide (SOMATULINE AUTOGEL)
UGIOCTLAR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Duration of approved treatment updated</i>	Symptomatic Management of Functional Carcinoid and Neuroendocrine Tumors of the GI Tract using Octreotide (SANDOSTATIN LAR)
GUTEM	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Eligibility updated</i>	Therapy for Advanced Renal Cancer using Temsirolimus
ULKMFRUX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Duration of approved treatment updated</i>	Treatment of Symptomatic Myelofibrosis with Ruxolitinib
ULKPCVRUX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Duration of approved treatment updated</i>	Treatment of Polycythemia Vera with Ruxolitinib

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
LUAVCRIZ	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Eligibility updated</i>	Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib
ULUAVPMTN	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Duration of approved treatment updated</i>	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) with Pemetrexed
SAVDC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Treatment options, Contact Physician and institution name updated</i>	Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, Dactinomycin, and Cyclophosphamide

The following **BC Cancer Pre-Printed Orders (PPPOs)** have been reformatted:

CODE	Protocol Title
<b>BRAJANAS</b>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Anastrozole in Postmenopausal Women
<b>BRAJEXE</b>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Exemestane in Postmenopausal Women
<b>BRAJLET</b>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Letrozole in Postmenopausal Women
<b>BRAJLHRHT</b>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using a LHRH Agonist and Tamoxifen
<b>BRAJTAM</b>	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Tamoxifen
<b>BRAVANAS</b>	Palliative Therapy for Metastatic Breast Cancer using Anastrozole
<b>BRAVCLOD</b>	For Therapy of Bone Metastases in Breast Cancer using Oral Clodronate
<b>BRAVEXE</b>	Palliative Therapy for Advanced Breast Cancer using Exemestane
<b>BRAVLET</b>	Palliative Therapy for Advanced Breast Cancer using Letrozole
<b>BRAVMEG</b>	Palliative Therapy for Advanced Breast Cancer using Megestrol
<b>BRAVTAM</b>	Palliative Therapy for Breast Cancer using Tamoxifen
<b>CNAJ12TZRT</b>	Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Astrocytomas and Oligodendrogliomas with Radiation
<b>CNAJTZRT</b>	Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation
<b>CNB</b>	Therapy for Pituitary Adenomas using Bromocriptine
<b>CNCAB</b>	Therapy for Pituitary Adenomas using Cabergoline
<b>CNELTZRT</b>	Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy
<b>CNQUIN</b>	Therapy for Pituitary Adenomas using Quinagolide

<b>CODE</b>	<b>Protocol Title</b>
<b>GIAJCAP</b>	Adjuvant Therapy of Colon Cancer using Capecitabine
<b>GIAVCAP</b>	Palliative Therapy of Advanced Colorectal Cancer using Capecitabine
<b>GIPAVCAP</b>	Second-Line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma using Capecitabine
<b>GUPNSAA</b>	Non-Steroidal Treatment of Prostate Cancer
<b>HNNAVCAP</b>	Treatment of Recurrent Or Metastatic Nasopharyngeal Cancer with Capecitabine
<b>HNSAVTAM</b>	Treatment of Recurrent/Metastatic Salivary Gland Cancers of the Head and Neck with Tamoxifen
<b>LUAVAFAT</b>	First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Afatinib
<b>ULUAVCER</b>	Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Ceritinib
<b>LUAVCRIZ</b>	Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib
<b>LUAVCRIZF</b>	First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Afatinib
<b>LUAVERL</b>	Second- or Later-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Erlotinib
<b>LUAVGEFF</b>	First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Gefitinib
<b>LUAVMTNE</b>	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) with Erlotinib After First-Line Chemotherapy
<b>LUSCPOE</b>	Palliative Therapy of Extensive Stage Small Cell Lung Cancer (SCLC) with Oral Etoposide
<b>LYCHLOR</b>	Therapy for Low Grade Lymphoma and Chronic Lymphocytic Leukemia using Chlorambucil
<b>LYCSPA</b>	Cyclosporine for Cytopenias Associated with Lymphoproliferative Disorder of Large Granular Lymphocytes
<b>ULYMFBOX</b>	Treatment for Refractory Cutaneous T-cell Lymphoma using Bexarotene
<b>MYMP</b>	Treatment of Multiple Myeloma using Melphalan and Prednisone



## WEBSITE RESOURCES AND CONTACT INFORMATION

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604-877-6000 x 673028		<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Provincial Systemic Therapy Program	604-877-6000 x 672247		<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
To update contact information of any CON sites, please contact:			<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Oncology Drug Information	604-877-6275		<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
Nurse Educators	604-877-6000 x 672638		<a href="mailto:nursinged@bccancer.bc.ca">nursinged@bccancer.bc.ca</a>
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Pharmacy Professional Practice	604-877-6000 x 672247		<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
Provincial Professional Practice Nursing			<a href="mailto:BCCancerPPNAdmin@ehcnet.phsa.ca">BCCancerPPNAdmin@ehcnet.phsa.ca</a>
OSCAR	888-355-0355	604-708-2051	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a>
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a>
Pharmacy Oncology Certification	250-712-3900 x 686820		<a href="mailto:rxchemocert@bccancer.bc.ca">rxchemocert@bccancer.bc.ca</a>
BC Cancer-Abbotsford	604-851-4710 Toll Free 877-547-3777		
BC Cancer-Prince George (Centre for the North)	250-645-7300 Toll Free 888-775-7300		
BC Cancer-Surrey	604-930-2098 Toll Free 800-523-2885		
BC Cancer-Kelowna	250-712-3900 Toll Free 888-563-7773		
BC Cancer-Vancouver	604-877-6000 Toll Free 800-663-3333		
BC Cancer-Victoria	250-519-5500 Toll Free 800-670-3322		

## EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)  
 Mario de Lemos, PharmD, MSc(Oncol)  
 Caroline Lohrisch, MD

Ava Hatcher, RN, MN, CON(c)  
 Naren Bollipalli, BSc(Pharm)